205 related articles for article (PubMed ID: 11188777)
1. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.
Achiron A; Miron S
Mult Scler; 2000 Oct; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777
[TBL] [Abstract][Full Text] [Related]
2. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
Stuerzebecher S; Martin R
Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
Humle Jorgensen S; Sorensen PS
J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
[TBL] [Abstract][Full Text] [Related]
4. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
Holmøy T
Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
[TBL] [Abstract][Full Text] [Related]
5. [Activation of T cells in experimental autoimmune encephalomyelitis and multiple sclerosis].
Rodríguez-Rodríguez Y; Suárez-Luis I
Rev Neurol; 2003 Apr 1-15; 36(7):649-52. PubMed ID: 12666047
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.
Stojkov D; Lavrnja I; Pekovic S; Dacic S; Bjelobaba I; Mostarica-Stojkovic M; Stosic-Grujicic S; Jovanovic S; Nedeljkovic N; Rakic L; Stojiljkovic M
J Neurol Sci; 2008 Apr; 267(1-2):76-85. PubMed ID: 17996253
[TBL] [Abstract][Full Text] [Related]
7. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis.
Gold BG; Voda J; Yu X; McKeon G; Bourdette DN
J Neurosci Res; 2004 Aug; 77(3):367-77. PubMed ID: 15248293
[TBL] [Abstract][Full Text] [Related]
8. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE).
Ziemssen T; Ziemssen F
Autoimmun Rev; 2005 Sep; 4(7):460-7. PubMed ID: 16137612
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated remyelination: relevance to multiple sclerosis.
Bieber A; Asakura K; Warrington A; Kaveri SV; Rodriguez M
Mult Scler; 2000 Oct; 6 Suppl 2():S1-5; discussion S33. PubMed ID: 11188771
[TBL] [Abstract][Full Text] [Related]
10. Experimental autoimmune encephalomyelitis mediated by CD8+ T cells.
Ji Q; Goverman J
Ann N Y Acad Sci; 2007 Apr; 1103():157-66. PubMed ID: 17376824
[TBL] [Abstract][Full Text] [Related]
11. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.
Li FQ; Sempowski GD; McKenna SE; Laskowitz DT; Colton CA; Vitek MP
J Pharmacol Exp Ther; 2006 Sep; 318(3):956-65. PubMed ID: 16740622
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
Reichardt HM; Gold R; Lühder F
Expert Rev Neurother; 2006 Nov; 6(11):1657-70. PubMed ID: 17144780
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with atorvastatin and minocycline suppresses severity of EAE.
Luccarini I; Ballerini C; Biagioli T; Biamonte F; Bellucci A; Rosi MC; Grossi C; Massacesi L; Casamenti F
Exp Neurol; 2008 May; 211(1):214-26. PubMed ID: 18346732
[TBL] [Abstract][Full Text] [Related]
15. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
16. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
Bolton C
Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
[TBL] [Abstract][Full Text] [Related]
17. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
Soelberg Sorensen P
Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
[TBL] [Abstract][Full Text] [Related]
18. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.
Sriram S; Steiner I
Ann Neurol; 2005 Dec; 58(6):939-45. PubMed ID: 16315280
[TBL] [Abstract][Full Text] [Related]
19. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
Wang D; Ayers MM; Catmull DV; Hazelwood LJ; Bernard CC; Orian JM
Glia; 2005 Aug; 51(3):235-40. PubMed ID: 15812814
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant therapy in multiple sclerosis.
Mirshafiey A; Mohsenzadegan M
Immunopharmacol Immunotoxicol; 2009; 31(1):13-29. PubMed ID: 18763202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
